NASDAQ: AMPH
Amphastar Pharmaceuticals Inc Stock

$19.59-0.04 (-0.2%)
Updated Jul 21, 2026
Why Price Moved
AMPH Price
$19.59
Fair Value Price
N/A
Market Cap
$863.78M
52 Week Low
$16.65
52 Week High
$31.26
P/E
11.46x
P/B
1.12x
P/S
1.23x
PEG
0.45x
Dividend Yield
N/A
Revenue
$720.53M
Earnings
$79.23M
Gross Margin
47.3%
Operating Margin
17.84%
Profit Margin
11%
Debt to Equity
1.13
Operating Cash Flow
$169M
Beta
0.57
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A

AMPH Overview

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine AMPH's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
C
AMPH
Ranked
#26 of 55

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important AMPH news, forecast changes, insider trades & much more!

AMPH News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AMPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AMPH ($19.59) is trading below its intrinsic value of $23.12, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AMPH is good value based on its earnings relative to its share price (11.46x), compared to the US market average (12.07x)
P/E vs Market Valuation
AMPH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more AMPH due diligence checks available for Premium users.

Valuation

AMPH price to earnings (PE)

For valuing profitable companies with steady earnings

Company
11.46x
Industry
-8.54x
Market
12.07x
AMPH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AMPH is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

AMPH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.12x
Industry
1.57x
AMPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AMPH price to earnings growth (PEG)

For valuing profitable companies with growth potential

AMPH is good value based... subscribe to Premium to read more.
PEG Value Valuation

AMPH's financial health

Profit margin

Revenue
$171.2M
Net Income
$6.4M
Profit Margin
3.8%
AMPH's Earnings (EBIT) of $128.56M... subscribe to Premium to read more.
Interest Coverage Financials
AMPH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.6B
Liabilities
$874.8M
Debt to equity
1.13
AMPH's short-term assets ($633.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMPH's long-term liabilities ($710.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMPH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AMPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$47.8M
Investing
-$16.7M
Financing
-$30.2M
AMPH's operating cash flow ($168.88M)... subscribe to Premium to read more.
Debt Coverage Financials

AMPH vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
AMPHC$863.78M-0.20%11.46x1.12x
BIOAD$1.01B+1.48%-9.44x2.66x
PCRXB$1.01B+1.70%214.83x1.55x
EVO$710.25M+1.01%-3.15x0.86x
CRONB$1.05B0.00%N/A0.97x

Amphastar Pharmaceuticals Stock FAQ

What is Amphastar Pharmaceuticals's quote symbol?

(NASDAQ: AMPH) Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol AMPH. Amphastar Pharmaceuticals stock quotes can also be displayed as NASDAQ: AMPH.

If you're new to stock investing, here's how to buy Amphastar Pharmaceuticals stock.

What is the 52 week high and low for Amphastar Pharmaceuticals (NASDAQ: AMPH)?

(NASDAQ: AMPH) Amphastar Pharmaceuticals's 52-week high was $31.26, and its 52-week low was $16.65. It is currently -37.34% from its 52-week high and 17.69% from its 52-week low.

How much is Amphastar Pharmaceuticals stock worth today?

(NASDAQ: AMPH) Amphastar Pharmaceuticals currently has 44,092,919 outstanding shares. With Amphastar Pharmaceuticals stock trading at $19.59 per share, the total value of Amphastar Pharmaceuticals stock (market capitalization) is $863.78M.

Amphastar Pharmaceuticals stock was originally listed at a price of $8.75 in Jun 25, 2014. If you had invested in Amphastar Pharmaceuticals stock at $8.75, your return over the last 12 years would have been 123.89%, for an annualized return of 6.95% (not including any dividends or dividend reinvestments).

How much is Amphastar Pharmaceuticals's stock price per share?

(NASDAQ: AMPH) Amphastar Pharmaceuticals stock price per share is $19.59 today (as of Jul 21, 2026).

What is Amphastar Pharmaceuticals's Market Cap?

(NASDAQ: AMPH) Amphastar Pharmaceuticals's market cap is $863.78M, as of Jul 23, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Amphastar Pharmaceuticals's market cap is calculated by multiplying AMPH's current stock price of $19.59 by AMPH's total outstanding shares of 44,092,919.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.